BRAF and lung carcinoma: Several examples include the v600E BRAF mutation, which predicts response to specific BRAF inhibitors [49], as well as high BRCA1 expression predicting resistance to neoadjuvant gemcitabine/cisplatin chemotherapy in lung cancer [50].